Home/Pharma News
|
Posted 14/04/2017
Both Samsung and Aurobindo see a bright future for biosimilars. Samsung BioLogics, which is the specialized biotechnology arm of Samsung, raised almost US$2 billion in November 2016 via an initial public offering (IPO) that valued the company at US$7.9 billion. This, according to Robert Wessman, Chairman and CEO at Alvogen, ‘underlines the confidence of the market in biosimilar companies’. Especially when considering that Samsung BioLogics only came into existence in 2011 [1].